Angiodynamics (ANGO) Cost of Revenue (2010 - 2026)

Angiodynamics (ANGO) has 17 years of Cost of Revenue data on file, last reported at $39.8 million in Q2 2026.

• Quarterly Cost of Revenue rose 4.99% year-over-year to $39.8 million in Q2 2026, while the trailing twelve-month figure through May 2026 was $145.3 million (up 7.78% YoY) and the FY2026 annual result came in at $145.3 million, up 7.78% from the prior year.
• Cost of Revenue advanced to $39.8 million in Q2 2026, from $36.9 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $44.7 million in Q2 2023 to a low of $30.8 million in Q3 2024.
• A 5-year average of $37.2 million and a median of $38.3 million in 2023 frame the typical range for Cost of Revenue.
• Annual changes were most pronounced in 2022 — Cost of Revenue gained 17.44% — and 2024, when it dropped 27.4%.
• Tracing ANGO's Cost of Revenue over 5 years: stood at $40.4 million in 2022, then declined by 3.82% to $38.8 million in 2023, then decreased by 15.13% to $32.9 million in 2024, then rose by 5.19% to $34.6 million in 2025, then increased by 14.96% to $39.8 million in 2026.
• The last three Cost of Revenue figures came in at $39.8 million (Q2 2026), $36.9 million (Q1 2026), and $34.6 million (Q4 2025), per Business Quant data.